$Plus Therapeutics (PSTV.US)$ NEWS Plus Therapeutics Provide...
NEWS
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Positive Acquisition of CNSide™ diagnostic platform to enhance LM diagnostic accuracy. Successful presentation of topline data from the FORESEE trial meeting primary endpoint. Potential partnering opportunities for CNSide™ to expand market size. Expected attractive near-term return on investment for stockholders. Negative Current tests like MRI and cytology are lacking sensitivity in diagnosing LM. Difficulty in diagnosing LM, with actual incidence potentially higher than diagnosed. Long-term impact on the total addressable market remains to be seen.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
596Followers
70Following
3800Visitors
Follow